
(Click on the 'Details' column to view details on interfaces and similar patterns of amino acids)
Click on the 'View' column to view patterns on the structural viewer)
PDB | Ligand | Drug | Indication | Macromolecule/ Organism |
Pfam | Binding_Interfaces (View) | Details |
---|---|---|---|---|---|---|---|
1b2i | AMH | Tranexamic acid (DB00302) | Tranexamic acid is an antifibrinolytic used to reduce or prevent hemorrhagic episodes, especially in the context of hyperfibrinolytic disorders. | PROTEIN (PLASMINOGEN) (Homo sapiens) | Kringle | ||
1cea | ACA | Aminocaproic acid (DB00513) | Aminocaproic acid is an antifibrinolytic agent used to induce clotting postoperatively. | PLASMINOGEN (Homo sapiens) | Kringle | ||
1ceb | AMH | Tranexamic acid (DB00302) | Tranexamic acid is an antifibrinolytic used to reduce or prevent hemorrhagic episodes, especially in the context of hyperfibrinolytic disorders. | PLASMINOGEN (Homo sapiens) | Kringle | ||
1f5l | AMR | Amiloride (DB00594) | Amiloride is a pyrizine compound used to treat hypertension and congestive heart failure. | UROKINASE-TYPE PLASMINOGEN ACTIVATOR (Homo sapiens) | Trypsin | ||
1pk2 | ACA | Aminocaproic acid (DB00513) | Aminocaproic acid is an antifibrinolytic agent used to induce clotting postoperatively. | TISSUE-TYPE PLASMINOGEN ACTIVATOR (Homo sapiens) | Kringle | ||
2pk4 | ACA | Aminocaproic acid (DB00513) | Aminocaproic acid is an antifibrinolytic agent used to induce clotting postoperatively. | HUMAN PLASMINOGEN KRINGLE 4 (Homo sapiens) | Kringle | ||
6dcm | ACA | Aminocaproic acid (DB00513) | Aminocaproic acid is an antifibrinolytic agent used to induce clotting postoperatively. | PLASMINOGEN (Homo sapiens) | NA | ||
6nmb | AMH | Tranexamic acid (DB00302) | Tranexamic acid is an antifibrinolytic used to reduce or prevent hemorrhagic episodes, especially in the context of hyperfibrinolytic disorders. | UROKINASE-TYPE PLASMINOGEN ACTIVATOR (Homo sapiens) | Trypsin | ||
PDB | Ligand | Drug | Indication | Macromolecule/ Organism |
Pfam | Binding_Interfaces (View) | Details |